News Gilead could make a move for Galapagos within weeks The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised to acquire it.
News Gilead goes full throttle on CAR-Ts with $567m acquisition Gilead hopes CDL technology will create therapies targeting solid tumours
News GSK's newly approved HIV treatment Juluca expected to domina... The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient combination that will compete with Gilead's nearly-approved three-drug re
News Cellectis gets FDA go-ahead to restart fatal CAR-T trial Regulator agrees to restart phase 1 trial of UCART 123
News Novartis files CAR-T in Europe in broader use than Gilead ri... Swiss pharma chasing EU licence in NHL and ALL indications
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
